COPENHAGEN, Denmark – On October 27, 2025, Evaxion A/S announced that Dr. Helen Tayton‑Martin will become the company’s Chief Executive Officer, stepping into the role on November 24, 2025. She will also resign from the Evaxion Board of Directors upon assuming the CEO position.
Dr. Tayton‑Martin holds a Ph.D. in molecular immunology and an MBA from London Business School. She co‑founded the cancer‑focused biotech Adaptimmune, where she served as Chief Operating Officer and later Chief Business & Strategy Officer for 17 years, overseeing trans‑Atlantic growth, multiple clinical collaborations, and the company’s Nasdaq IPO.
The appointment comes as Evaxion continues to advance its AI‑Immunology platform, recently highlighted by the out‑licensing of EVX‑B3 to MSD and the presentation of EVX‑01 data at ESMO. Her experience in partnership development and commercialization is expected to accelerate the company’s pipeline and market positioning.
In addition to the CEO change, Evaxion announced that Jens Bitsch‑Norhave will join the Board as an adviser and observer, with the intention of seeking election as a board member at the 2026 Annual General Meeting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.